Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818619 | 0.82 | HTR1A (0.35) | AADATHTR1ADRD2KCNH2 | |
| SCHEMBL3778731 | 0.81 | BPTF (0.43) | AADATHTR1ADRD2KCNH2BPTF | |
| SCHEMBL3403994 | 0.78 | CDK4 (0.37) | AADATHTR1ADRD2KCNH2 | |
| SCHEMBL3777717 | 0.78 | TSHR (0.43) | HTR1ADRD2 | |
| SCHEMBL23249299 | 0.75 | DRD2 (0.32) | HTR1ADRD2DRD3 | |
| SCHEMBL2288096 | 0.75 | KCNH2 (0.39) | HTR1ADRD2KCNH2 | |
| SCHEMBL2292976 | 0.75 | KCNH2 (0.39) | HTR1ADRD2KCNH2 | |
| SCHEMBL4554113 | 0.72 | NOTUM (0.32) | — | |
| SCHEMBL31057621 | 0.72 | NOTUM (0.32) | — | |
| SCHEMBL13492064 | 0.69 | KCNH2 (0.39) | HTR1ADRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257551-B1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-8349828-B2 | Azatricyclic antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ZYX, AZI2, NAT1 | AADAT 2968/4885HTR1A 1449/4885DRD2 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.